Novartis is expanding its drug development pipeline by acquiring Myricx Bio, which adds novel NMTi payloads to its antibody-drug conjugates (ADC) portfolio. While the commercial impact of this acquisition is expected to take several years, Novartis also has promising late-stage assets like Avidity’s del-brax and Ionis’s pelacarsen, which could generate multibillion-dollar sales. Pelacarsen is particularly notable as it will soon provide key data on whether lowering lipoprotein(a) can reduce cardiovascular risks, with pivotal results expected in the second half of the year. This strategy aligns with Novartis’ focus on organic growth complemented by targeted small acquisitions and in-licensing deals.
Novartis has agreed to acquire Myricx Bio, a UK-based oncology company developing novel antibody-drug conjugates (ADCs), for up to $1.5 billion including $1.1 billion upfront. This acquisition combines Novartis's oncology expertise with Myricx Bio's ...
Novartis has agreed to acquire UK biotech Myricx Bio for up to $1.5 billion, including $1.1 billion cash upfront, to enhance its oncology portfolio with Myricx's novel antibody-drug conjugate (ADC) payloads. Myricx Bio specializes in a first-in-class...
